- Home
- MRM vs CODX Comparison
MRM vs CODX Comparison
Compare MRM & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- CODX
- Stock Information
- Founded
- MRM 2000
- CODX 2013
- Country
- MRM Japan
- CODX United States
- Employees
- MRM N/A
- CODX N/A
- Industry
- MRM Other Consumer Services
- CODX Medical/Dental Instruments
- Sector
- MRM Consumer Discretionary
- CODX Health Care
- Exchange
- MRM Nasdaq
- CODX Nasdaq
- Market Cap
- MRM 10.4M
- CODX 9.8M
- IPO Year
- MRM 2020
- CODX 2017
- Fundamental
- Price
- MRM $2.19
- CODX $0.25
- Analyst Decision
- MRM
- CODX Buy
- Analyst Count
- MRM 0
- CODX 2
- Target Price
- MRM N/A
- CODX $5.50
- AVG Volume (30 Days)
- MRM 6.6M
- CODX 825.6K
- Earning Date
- MRM 05-20-2025
- CODX 08-14-2025
- Dividend Yield
- MRM N/A
- CODX N/A
- EPS Growth
- MRM 27.65
- CODX N/A
- EPS
- MRM 0.18
- CODX N/A
- Revenue
- MRM $52,786,758.00
- CODX $3,497,583.00
- Revenue This Year
- MRM N/A
- CODX N/A
- Revenue Next Year
- MRM N/A
- CODX $42.11
- P/E Ratio
- MRM $14.33
- CODX N/A
- Revenue Growth
- MRM 21.55
- CODX N/A
- 52 Week Low
- MRM $0.34
- CODX $0.23
- 52 Week High
- MRM $8.39
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- MRM 64.42
- CODX 43.59
- Support Level
- MRM $1.10
- CODX $0.24
- Resistance Level
- MRM $3.53
- CODX $0.27
- Average True Range (ATR)
- MRM 0.33
- CODX 0.02
- MACD
- MRM 0.13
- CODX -0.00
- Stochastic Oscillator
- MRM 44.81
- CODX 31.17
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.